Resistance to dihydroartemisinin [7]

Emerging Infectious Diseases

Volumn 12, Issue 11, 2006, Pages 1798-1799

  Cojean, Sandrine ^a,b   Hubert, Véronique ^a   Le Bras, Jacques ^a,b,c   Durand, Rémy ^a,c,d  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c AVICENNE HOSPITAL   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMISIN DERIVATIVE; ARTEMISININ; BENFLUMETOL; DIHYDROARTEMISININ; MEFLOQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROQUINGHAOSU; SESQUITERPENE; UNCLASSIFIED DRUG;

DNA POLYMORPHISM; DNA SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; IC 50; IN VITRO STUDY; LETTER; MALARIA; MONOTHERAPY; SPECIES DIFFERENCE; WORLD HEALTH ORGANIZATION; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; PLASMODIUM FALCIPARUM; SESQUITERPENES;

EID: 33750563820     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1211.060903     Document Type: Letter

References (10)

1. Attaran A, Barnes KI, Curtis C, D'Alessandro U, Fanello C, Galinski MR, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet. 2004;363:237-40.
2. Mutabingwa TK. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop. 2005;95:305-15.
3. Ittarat W, Pickard AL, Rattanasinganchan P, Wilairatana P, Looareesuwan S, Emery K, et al. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg. 2003;68:147-52.
4. Grandesso F, Hagerman A, Kamara S, Lam E, Checchi F, Balkan S, et al. Low efficacy of the combination artesunate plus amodiaquine for uncomplicated falciparum malaria among children under 5 in Kailahun, Sierra Leone. Trop Med Int Health. 2006;11:1017-21.
5. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of Plasmodium falciparum field isolates to invitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005;366:1960-3.
6. Anderson TJC, Nair S, Qin H, Singlam S, Brockman A, Paiphun L, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother. 2005;49:2180-8.
7. Le Bras J, Andrieu B, Hatin I, Savel J, Coulaud JP. Plasmodium falciparum: interpretation of the semi-microtest of in vitro chemosensitivity by H3-hypoxanthine incorporation. Pathol Biol. 1984;32:463-6.
8. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol. 2005;12:628-9.
9. Ringwald P, Bickii J, Basco LK. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg. 1999;61:187-92.
10. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol. 2006;44:2404-8.